Brainlab SE / DE0005207906

AD-HOC RELEASE PUBLICATION OF INSIDE INFORMATION IN THE FORM OF AN AD HOC ANNOUNCEMENT PURSUANT TO ARTICLE 17 OF REGULATION (EU) NO. 596/2014 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Munich, July 1, 2025— Brainlab SE and the selling shareholders decided today to postpone the planned IPO and listing of Brainlab SE. The start of trading of Brainlab SE’s shares in the Prime Standard of the Frankfurt Stock Exchange was scheduled for Thursday, July 3, 2025. An IPO at a later time remains under consideration by Brainlab and the selling shareholders.   About Brainlab  At Brainlab, we digitize medical workflows, from diagnosis to therapy, to offer clinicians and patients better treatment possibilities. Our innovative digital ecosystem forms the basis for modern healthcare technology in around 4000 healthcare institutions in 120 countries. At the forefront of health technology for over 35 years, Munich-based Brainlab employs around 2000 people with expertise across the entire healthcare value chain in 25 locations worldwide. Brainlab AG is currently in the process of converting to a Societas Europaea (SE). For more information, visit Brainlab. Press Contact
Bernadette Erwig
Communication & PR